TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival

Cell

Volumn 115, Issue 5, 2003, Pages 577-590

  Inoki, Ken ^a,b   Zhu, Tianqing ^a,b   Guan, Kun Liang ^a,b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; TUBERIN;

APOPTOSIS; ARTICLE; CELL ENERGY; CELL GROWTH; CELL PROTECTION; CELL SIZE; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; TRANSLATION REGULATION;

EID: 0345167800     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(03)00929-2     Document Type: Article

References (51)

1. Au K.S., Rodriguez J.A., Finch J.L., Volcik K.A., Roach E.S., Delgado M.R., Rodriguez E. Jr., Northrup H. Germ-line mutational analysis of the TSC2 gene in 90 tuberous-sclerosis patients. Am. J. Hum. Genet. 62:1998;286-294.
2. Brown E.J., Beal P.A., Keith C.T., Chen J., Shin T.B., Schreiber S.L. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature. 377:1995;441-446.
3. Browne G.J., Proud C.G. Regulation of peptide-chain elongation in mammalian cells. Eur. J. Biochem. 269:2002;5360-5368.
4. Corton J.M., Gillespie J.G., Hawley S.A., Hardie D.G. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229:1995;558-565.
5. Dan H.C., Sun M., Yang L., Feldman R.I., Sui X.M., Yeung R.S., Halley D.J., Nicosia S.V., Pledger W.J., Cheng J.Q. PI3K/AKT pathway regulates TSC tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem. 277:2002;35364-35370.
6. Dennis P.B., Jaeschke A., Saitoh M., Fowler B., Kozma S.C., Thomas G. Mammalian TOR. a homeostatic ATP sensor Science. 294:2001;1102-1105.
7. Fingar D.C., Salama S., Tsou C., Harlow E., Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16:2002;1472-1487.
8. Gao X., Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 15:2001;1383-1392.
9. Gao X., Zhang Y., Arrazola P., Hino O., Kobayashi T., Yeung R.S., Ru B., Pan D. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 4:2002;699-704.
10. Goncharova E.A., Goncharov D.A., Eszterhas A., Hunter D.S., Glassberg M.K., Yeung R.S., Walker C.L., Noonan D., Kwiatkowski D.J., Chou M.M.et al. Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation. A role for the Tsc2 tumor suppressor gene in pulmonary lymphangeioleiomyomatosis (LAM). J. Biol. Chem. 277:2002;30958-30967.
11. Hara K., Yonezawa K., Weng Q.P., Kozlowski M.T., Belham C., Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 273:1998;14484-14494.
12. Hardie D.G., Hawley S.A. AMP-activated protein kinase. the energy charge hypothesis revisited Bioessays. 23:2001;1112-1119.
13. Hardie D.G., Carling D., Carlson M. The AMP-activated/SNF1 protein kinase subfamily. metabolic sensors of the eukaryotic cell? Annu. Rev. Biochem. 67:1998;821-855.
14. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., Alessi D.R., Hardie D.G. Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2:2003;28.
15. Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S., Loukola A., Bignell G., Warren W., Aminoff M., Hoglund P.et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 391:1998;184-187.
16. Hong S.P., Leiper F.C., Woods A., Carling D., Carlson M. Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc. Natl. Acad. Sci. USA. 100:2003;8839-8843.
17. Horman S., Browne G., Krause U., Patel J., Vertommen D., Bertrand L., Lavoinne A., Hue L., Proud C., Rider M. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr. Biol. 12:2002;1419-1423.
18. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:2002;648-657.
19. Ito N., Rubin G.M. gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell. 96:1999;529-539.
20. Jaeschke A., Hartkamp J., Saitoh M., Roworth W., Nobukuni T., Hodges A., Sampson J., Thomas G., Lamb R. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell Biol. 159:2002;217-224.
21. Jenne D.E., Reimann H., Nezu J., Friedel W., Loff S., Jeschke R., Muller O., Back W., Zimmer M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 18:1998;38-43.
22. Kenerson H.L., Aicher L.D., True L.D., Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 62:2002;5645-5650.
23. Kimura N., Tokunaga C., Dalal S., Richardson C., Yoshino K., Hara K., Kemp B.E., Witters L.A., Mimura O., Yonezawa K. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells. 8:2003;65-79.
24. Kobayashi T., Minowa O., Sugitani Y., Takai S., Mitani H., Kobayashi E., Noda T., Hino O. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc. Natl. Acad. Sci. USA. 98:2001;8762-8767.
25. Krause U., Bertrand L., Hue L. Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes. Eur. J. Biochem. 269:2002;3751-3759.
26. Kwiatkowski D.J. Tuberous sclerosis. from tubers to mTOR Ann. Hum. Genet. 67:2003;87-96.
27. Kwiatkowski D.J., Zhang H., Bandura J.L., Heiberger K.M., Glogauer M., el-Hashemite N., Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11:2002;525-534.
28. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell. 10:2002;151-162.
29. Nave B.T., Ouwens M., Withers D.J., Alessi D.R., Shepherd P.R. Mammalian target of rapamycin is a direct target for protein kinase B. identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation Biochem. J. 344:1999;427-431.
30. Onda H., Lueck A., Marks P.W., Warren H.B., Kwiatkowski D.J. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104:1999;687-695.
31. Onda H., Crino P.B., Zhang H., Murphey R.D., Rastelli L., Gould Rothberg B.E., Kwiatkowski D.J. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol. Cell. Neurosci. 21:2002;561-574.
32. Potter C.J., Xu T. Mechanisms of size control. Curr. Opin. Genet. Dev. 11:2001;279-286.
33. Potter C.J., Huang H., Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell. 105:2001;357-368.
34. Potter C.J., Pedraza L.G., Xu T. Akt regulates growth by directly phosphorylating TSC2. Nat. Cell. Biol. 4:2002;659-665.
35. Proud C.G. Regulation of mammalian translation factors by nutrients. Eur. J. Biochem. 269:2002;5338-5349.
36. Radimerski T., Montagne J., Hemmings-Mieszczak M., Thomas G. Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes Dev. 16:2002;2627-2632.
37. Schmidt E.V. The role of c-myc in cellular growth control. Oncogene. 18:1999;2988-2996.
38. Scott P.H., Brunn G.J., Kohn A.D., Roth R.A., Lawrence J.C. Jr. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA. 95:1998;7772-7777.
39. Scott J.W., Norman D.G., Hawley S.A., Kontogiannis L., Hardie D.G. Protein kinase substrate recognition studied using the recombinant catalytic domain of AMP-activated protein kinase and a model substrate. J. Mol. Biol. 317:2002;309-323.
40. Sekulic A., Hudson C.C., Homme J.L., Yin P., Otterness D.M., Karnitz L.M., Abraham R.T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60:2000;3504-3513.
41. Shah O.J., Anthony J.C., Kimball S.R., Jefferson L.S. 4E-BP1 and S6K1. translational integration sites for nutritional and hormonal information in muscle Am. J. Physiol. Endocrinol. Metab. 279:2000;E715-E729.
42. Shioi T., McMullen J.R., Tarnavski O., Converso K., Sherwood M.C., Manning W.J., Izumo S. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation. 107:2003;1664-1670.
43. Soltoff S.P. Rottlerin is a mitochondrial uncoupler that decreases cellular ATP levels and indirectly blocks protein kinase Cdelta tyrosine phosphorylation. J. Biol. Chem. 276:2001;37986-37992.
44. Stein S.C., Woods A., Jones N.A., Davison M.D., Carling D. The regulation of AMP-activated protein kinase by phosphorylation. Biochem. J. 345:2000;437-443.
45. Sutherland C.M., Hawley S.A., McCartney R.R., Leech A., Stark M.J., Schmidt M.C., Hardie D.G. Elm1p is one of three upstream kinases for the Saccharomyces cerevisiae SNF1 complex. Curr. Biol. 13:2003;1299-1305.
46. Tapon N., Ito N., Dickson B.J., Treisman J.E., Hariharan I.K. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell. 105:2001;345-355.
47. Tee A.R., Fingar D.C., Manning B.D., Kwiatkowski D.J., Cantley L.C., Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. USA. 99:2002;13571-13576.
48. van Slegtenhorst M., Nellist M., Nagelkerken B., Cheadle J., Snell R., van den Ouweland A., Reuser A., Sampson J., Halley D., van der Sluijs P. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum. Mol. Genet. 7:1998;1053-1057.
49. Yoo L.I., Chung D.C., Yuan J. LKB1-a master tumour suppressor of the small intestine and beyond. Nat. Rev. Cancer. 2:2002;529-535.
50. Young J., Povey S. The genetic basis of tuberous sclerosis. Mol. Med. Today. 4:1998;313-319.
51. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N.et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108:2001;1167-1174.